NCT06779539View on ClinicalTrials.gov

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

June 12, 2028

Study Completion Date

December 12, 2030

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Ensartinib

Ensartinib 225 mg oral once daily 12 weeks

All Listed Sponsors

lead

West China Hospital

OTHER